Results 251 to 260 of about 112,243 (300)

Molecular insight on the role of the phosphoinositide PIP3 in regulating the protein kinases Akt, PDK1, and BTK. [PDF]

Biochem Soc Trans
Shaw AL, Burke JE.
europepmc   +1 more source

Decoding HIV‐1 Next Move Through Matrix Protein p17 Quasi‐Species

MicrobiologyOpen, Volume 15, Issue 2, April 2026.
HIV‐1 mutants expressing clonogenic HIV‐1 matrix protein p17 variants (vp17s) are spreading, increasing their prevalence worldwide. In RNA viruses, quasi‐species are transmitted among hosts, leading to the generation of new master sequences. We developed a next‐generation sequence approach to evaluate the frequency of vp17 quasi‐species in people ...
Serena Messali, Anna Bertelli, Marta Giovanetti, Leonardo Sclavi, Massimo Ciccozzi, Mark Slevin, Arnaldo Caruso, Francesca Caccuri   +7 more
wiley   +1 more source

Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in <i>NF2</i>-Related Human Schwannoma Cells. [PDF]

Int J Mol Sci
Nagel A, Hass EW, Hayes H, Huelbes L, Oliveira S, Hardin HM, Marasigan M, Nisenbaum E, Misztal C, Telischi FF, Ivan ME, Liu XZ, Bracho OR, Dinh CT, Fernandez-Valle C.   +14 more
europepmc   +1 more source

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Yamamoto Y.
europepmc   +1 more source

Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Cardiovasc Toxicol
Garcia A, Kayani AMA, Navarro-Martinez DA, Lemus-Zamora RE, Salama-Frisbie R, Fretz T, Tellez-Garcia E, Aviles E, Patel B.   +8 more
europepmc   +1 more source

Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus. [PDF]

World J Stem Cells
Luo C, Yu XM, Hua LY, Zeng MQ, Xu H, Duan CZ, Xu SY, Sun D, Ye LY, He DJ.   +9 more
europepmc   +1 more source

B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting. [PDF]

Front Immunol
Zhu Y, Gao L, Han Y, Liu F, Xie X, Dai X, Wang Y, Guo Y, Luo C, Chen Y, Huang P, Du Z.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic potential of phosphoinositide 3-kinase inhibitors

Expert Opinion on Therapeutic Patents, 2004
Originally discovered as oncogene-associated lipid kinases more than 15 years ago, the family of phosphoinositide 3-kinase (PI 3-K) enzymes has recently emerged as an important therapeutic target in human pathophysiology. After more than a decade with only a few inhibitors with low activity, poor isoform or kinase selectivity or unacceptable ...
Beth E Drees, Gordon B Mills, Christian Rommel, Glenn D Prestwich   +3 more
openaire   +1 more source

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents

Current Opinion in Pharmacology, 2003
The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biological roles. Until now, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms ...
Stephen G, Ward, Peter, Finan
openaire   +2 more sources